title: Prognostic factors in adult patients with solid cancers and bone marrow metastases.
abstract: BACKGROUND
  Solid cancers with bone marrow metastases are rare but lethal. This study aimed to identify clinical factors predictive of survival in adult patients with solid cancers and bone marrow metastases.
  
  
  METHODS
  A total of 83 patients were enrolled consecutively between January 1, 2000 and December 31, 2012. Bone marrow metastases were confirmed by biopsies. Patient clinical features and laboratory data were analyzed for associations.
  
  
  RESULTS
  The median age of the patients was 54 years (range, 23-88 years), and 58% were male. The 3 most common primary tumor locations were the stomach (32 patients, 39%), prostate (16 patients, 19%), and lungs (12 patients, 15%). The median overall survival was 49 days (range, 3-1423 days). Patients with Eastern Cooperative Oncology Group performance status 1, cancers of prostate origin, platelet counts over 50,000/ml, and undergoing antitumor therapies had a significantly better prognosis in the multivariate analysis. The median survival times were 173 and 33 days for patients with 2-3 more favorable parameters (n=24) and those with 0-1 (n=69), respectively (hazard ratio 0.30; 95% CI 0.17-0.52, p<0.001).
  
  
  CONCLUSIONS
  Solid cancers with bone marrow metastases are dismal and incurable diseases. Understanding prognostic factors to these diseases helps medical personnel to provide appropriate treatments and better inform patients about outcomes. Antitumor therapies may improve outcomes in selected patient cohorts.
authors: Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, and School of Medicine, Chang Gung University, Taoyuan, Taiwan E-mail : wenchi3992@yahoo.com.tw, js1101@adm.cgmh.org.tw.
authors: Yu-Shin
authors: YS
authors: Hung
authors: Wen-Chi
authors: WC
authors: Chou
authors: Tai-Di
authors: TD
authors: Chen
authors: Tse-Ching
authors: TC
authors: Chen
authors: Po-Nan
authors: PN
authors: Wang
authors: Hung
authors: H
authors: Chang
authors: Hung-Chih
authors: HC
authors: Hsu
authors: Wen-Chi
authors: WC
authors: Shen
authors: Wei-Hong
authors: WH
authors: Cheng
authors: Jen-Shi
authors: JS
authors: Chen
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy / Q000556:secondary*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001663:Bilirubin / Q000097:blood; D019046:Bone Marrow Neoplasms / Q000097:blood / Q000556:secondary* / Q000628:therapy; D005260:Female; D006304:Health Status; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000097:blood / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D011379:Prognosis; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology* / Q000628:therapy; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000097:blood / Q000473:pathology* / Q000628:therapy; D055815:Young Adult
chemical_list: D001663:Bilirubin